TO/SB/08B (08-00)

Please type a plus sign (+) inside this box \rightarrow $\boxed{+}$

		```
Substitute for Form 1449A/PTO		Complete it known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/955,444 (2), 2
(use as many sheets an necessary)	Filing Date	September 17, 2001
0, 7,6	First Named Inventor	James M. Wilson et al 3
DEC 1 1 2001	Group Art Unit	1645   635
DEC 1 2001	Examiner Name	
Sheet 1 of 2	Attorney Docket Number	UPN-N2605

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiners Cite Initials No.1									
DW	AR	R. KOTIN et al, "Site-Specific integration by Adeno-Associated Virus", Proc. Natl. Acad. Sci. USA, 87:2211-2215 (March, 1990)							
	AS	K. FISHER et al, "Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy", Nature Medicine, 3(3):306-312 (March, 1997)							
	AT	X. XIAO et al, "Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector", Journal of Virology, 70(11):8098-8108 (November, 1996)	,						
	AU	R. SNYDER et al, "Persistent and Therapeutic Concentrations of Human Factor IX in Mice After Hepatic Gene Transfer of Recombinant AAV Vectors", Nature Genetics, 16:270-276 (July, 1997)							
	AV	N. MUZYCZKA, "Use of Adeno-Associated Virus as a General Transduction Vector for Mamalian Cells", Current Topics in Microbiology and Immunology, 158:97-129 (1992)							
,	AW	R. SAMULSKI et al, "Targeted Integration of Adeno-Associated Virus (AAV) into Human Chromosome 19", EMBO Journal, 10(12):3941-3950 (December, 1991)							
	AX	K. BERNS, "Parvoviridae: the Viruses and their Replication, in B. N. Fields et al, Fundamental Virology, 3 rd ed., Chapter 31, pp. 1017-1041 (Lippincott-Raven Publishers, Philadelphia, PA) (1996)							
PV	AY	R. SNYDER et al, "Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Protein", Journal of Virology, 67(10):6096-6104 (October, 1993)							

	Date Considered	763
--	--------------------	-----

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for Form 1449A/PTO		Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/955,444 DEC
(use as many sheets as necessary)	Filing Date	September 27, 2001 200
OIPE	First Named Inventor	James M. Wilson et al
DEC 1 1 2001	Group Art Unit	1645 1635
	Examiner Name	
Sheet 2 MADEMARK 2	Attorney Docket Number	UPN-N2605

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiners Initials	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.						
PY AZ		K. BERNS, "Parvovirus Replication", Microbiological Reviews, 54(3):316-329 (September, 1990)					
	AAR	C. BALAGUÉ et al, "Adeno-Associated Virus Rep78 Protein and Terminal Repeats Enhance Integration of DNA Sequences into the Cellular Genome", Journal of Virology, 71(4):3299-3306 (April, 1997)					
	AAS	R. SUROSKY et al, "Adeno-Associated Virus Rep Proteins Target DNA Sequences to a Unique Locus in the Human Genome", Journal of Virology, 71(10):7951-7959 (October, 1997)					
	AAT	X. XIAO et al, "Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous System", Experimental Neurology, 144:113-124 (1997)					
BH	AAU	J. CHIORINI et al, "Cloning and Characterization of Adeno-Associated Virus Type 5", J. Virol., 73(2):1309-1319 (February, 1999)					
		·					
		•					

Examiner Signature	BN	Ar	A	Hen			Date Considere	ed	6	17103	
+ 221 1 2 (12 12 2)	T 1.1 14 C	70				A COURS CO.	A D			10 1 0	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Substitute 1	for Form 1449A/P	го			Complete if Known			
	ATION DISCLOS			Application Number	09/955,444			
	(use as man	y sheets as	necessary)	Filing Date	September 17, 2001			
		PATENT	UN 2 4 2000 CD	First Named Inventor	James M. Wilson et al			
		THE STATE OF THE S	2002	Group Art Unit	1645   635			
		~**	DEMARK OFFICE	Examiner Name				
Sheet	2	of	. 2	Attorney Docket Number	UPN-N2605			

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiners Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Þ'n	AAV	X. XIAO et al, "Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus", J. Virol., 72(3):2224-2232 (March, 1998)	
7.		RECEIVED	
		JUN 2 8 2002	
		TECH CENTER 1600/2900	

Examiner Signature	Bayer Shama	Date Considered	6 13/03	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Substitute f	for Form 1449A/PTC	)		TECH CENTER 1600/290@complete if Known			
	ATION DISCLOST			Application Number	09/955,444		
	(use as many	_	s necessary)	Filing Date	September 17, 2001		
		4	10	First Named Inventor James M. Wilson et al			
	PATEL JUN 2		1	Group Art Unit	1645   6 ) )		
	THADEMA	RK OFFIC	5/	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	UPN-N2605		

U.S. PATENT DOCUMENTS									
Examiner	Cite	U.S. Pate	nt Document	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant			
Initials*	No.1	Kind Code ² Number (if known)		Cited Document	Cited document MM-DD-YYYY	Passages or Relevant Figures Appear			
	<del>                                     </del>								
	<u> </u>								
					1				

				FOR	EIGN PATENT DOCUMENTS			
Examiner Initials	Cite No. ¹		Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
		Office ³		d Code ⁵ known)		MM-DD-YYYY		
BY	AL	wo	WO96/00587	Al	R. Samulski	01/11/1996		
	AM	wo	WO99/61601	A2	J. Chiorini	12/02/1999		
Bh	AN	wo	WO01/70276	A2	J. Chiorini	09/27/2001		

Examiner Signature	Brin & Dlam	Date Considered	613/03

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ¹⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

#14/1.0.5

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1449/PTO	Application Number	09/955,444	
INFORMATION DISCLOSURE	Filing Date	September 17, 2001	
STATEMENT BY APPLICANT	First Named Inventor	James M. Wilson et al	
(Use as many sheets as necessary)	Group Art Unit	1635	
OIPE	Examiner Name	Brian A. Whiteman	
Sheet 1 1	Attorney Docket Number	UPN-N2605	
APR 1 4 2003 =			

	<del></del>	7 2000	<u> </u>	FOREI	GN PATENT DOCUM	ENTS		
Examiner Initials*	No.	Country	Foreign Patent Docum  Code ³ - Number ⁴ -Kind Co		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
Br	<del>40-</del>	PCT- WINI	WO 01/83692	A2	11-08-2001	The Trustees of the University of Pennsylvania, et al		
pr.	*** **********************************	MI()	WO 00/28061	A3	05-18-2000	The Trustees of the University of Pennsylvania, et al		

## RECEIVED

APR 1 5 2003

TECH CENTER 1600/2900

## OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume, issue, number(s), publisher, city and/or country where published					
Br	AAW	AURICCHIO, A., et al, "Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins", J. Clin. Invest., 110(4):499-504 (August 2002).					
Examiner Signat	ture	Date Considered 6/3/03					

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00) Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO			Complete if Known				
	Substitute 101	101111 144	3/110	Application Number	Application Number 09/955,444			
	INFOR	(TAM	ON DISCLOSURE	Filing Date	September 17,	2001		
			T BY APPLICANT	First Named Inventor	James M. Wilson et al  1635			
	(Use	as many	sheets as necessary)	Group Art Unit	Group Art Unit 1635			
				Examiner Name	Brian A. White	man R		
	Sheet 1		of 2	Attorney Docket Number	UPN-N2605	- 1		
_						ું ગામ		
				U.S. PATENT DOCUMENTS		宝 药剂		
	Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns Lines Wifere Relevant Passages on Relevant Figures Appear		
		Number-Kind Code ^{2(if known)}			Cited Document	00%		
	Div	AA	US-2002-0132787-A1	09-19-2002	Eljamal et al	<del>-</del>		
	PL	AB	US-2002-0036454-A1	11-01-2001	Li et al			
				\				

			FOREIGNIA	ATENT DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant
	140.	Country Code3- Number4-Kind	Code ⁵ (if known)		Applicant of Cited Document	Passages or Relevant Figures Appear
_		·				
						<u> </u>

**Examiner Signature** Date

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent and the serial number of the patent serial patent and the serial number of the patent serial patent and the serial number of the patent number of the patent serial number of the patent number of the number o document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449	/PTO		Complete if Known		
Substitute for form 1445/110				Application Number	09/955,444	
INFO	ORMATI	ON [	DISCLOSURE	Filing Date	September 17, 2001	
	STATEMENT BY APPLICANT			First Named Inventor	James M. Wilson et al	
(1)	lse as many s	heets a	s necessary)	Group Art Unit	1635	
				Examiner Name	Brian A. Whiteman	
Sheet	2	of	2	Attorney Docket Number UPN-N2605		
Sheet	2	of	2	Attorney Docket Number	UPN-N2605	_

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse number(s), publisher, city and/or country where published	T ²
DW	AAX	FLOTTE ET AL, Gene Therapy in Cystic Fibrosis, CHEST 2001, Vol. 120, pp. 124s-131s, (September 2001)	
BN	AAY	KLINK ET AL, Gene Therapy of Cystic Fibrosis (CF) airways: A Review Emphasizing Targeting with Lactose, Glycoconjugate Journal, Vol. 18, pp. 731-740, (2001)	

Examiner Signature	n 11	Date	1171
1JA	vi la Like	Considered	& 1 (1())
	· Market		0, 3,()

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.